Adherence
Discontinuation of GLP-1 receptor agonists (GLP-1 RA) is significantly higher and reinitiation is significantly lower in patients without type 2 diabetes (T2D) compared to those with T2D, driven largely by insurance coverage and cost barriers rather than efficacy.
If you are taking a GLP-1 RA for weight loss without diabetes, be aware that insurance coverage is a major hurdle. Discontinuation rates are significantly higher for non-diabetics, often due to cost. If you face financial barriers, discuss coverage options or assistance programs with your provider immediately, as these factors heavily influence long-term adherence.
Most patients with overweight or obesity discontinue GLP-1 RA within 1 year, but those without T2D discontinue at higher rates and reinitiate at lower rates. Inequities in access and adherence to effective treatments have the potential exacerbate disparities in obesity.
Why this rating
Large retrospective cohort study (n=96,544) using real-world EHR data, though not a randomized controlled trial.
Source
Discontinuation and Reinitiation of GLP-1 Receptor Agonists Among US Adults with Overweight or Obesity
Patricia J Rodriguez et al. · medRxiv · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →